Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy effi...
Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer
About this item
Full title
Author / Creator
Liao, Jiatao , Lai, Hongyan , Liu, Chang , Zhang, Xin , Ou, Qiuxiang , Li, Qiaojuan , Li, Yan , Wang, Zhen , Liu, Cuicui , Wu, Xianghua , Wang, Huijie , Yu, Hui , Sun, Si , Zhao, Xinmin , Hu, Zhihuang , Zhang, Yao , Lin, Ying , Yu, Bo , Huang, Shenglin and Wang, Jialei
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Better biomarkers are needed to improve the efficacy of immune checkpoint inhibitors in lung adenocarcinoma (LUAD) treatment. We investigated the plasma extracellular vesicle (EV)‐derived long RNAs (exLRs) in unresectable/advanced LUAD to explore biomarkers for immunochemotherapy. Seventy‐four LUAD patients without targetable mutations receiving fi...
Alternative Titles
Full title
Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10323081
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10323081
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/cas.15804
